From the JP Morgan Conference: The Impact of the Inflation Reduction Act

John was at the JP Morgan conference and is here to discuss the key takeaways of the Inflation Reduction Act: the small-molecule penalty, the value of small-molecule drugs, the importance of incentivizing post-approval research, intellectual property, and non-coverage decisions at CMS. You’ll also hear John’s take on the demand for a more pro-patient agenda. There was a lot of focus on the role of policy and government, specifically in relation to the inflation reduction act and its impact on the life science and venture capital industries. Ready to reaffirm its values, Incubate will be focusing its energy on working with the White House and Congress to make necessary amendments to the legislation. They’ll also have a focus on education and awareness to ensure that policymakers understand the critical role they play in the healthcare landscape.Join us as we discuss:Why is there excitement for 2023 in the biotech sector, but also some anxiety?How does the organization, Incubate, plan to address the inflation reduction act?What Congress can be doing to create a more pro-patient agenda?